AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%
Tue, 12 Feb

AUROBINDO PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m43,36147,51452,69710.9%21.5%
Other incomeRs m331263639143.1%93.2%
TurnoverRs m43,69247,77753,33511.6%22.1%
ExpensesRs m33,10537,65141,83311.1%26.4%
Gross profitRs m10,2589,59410,61310.6%3.5%
DepreciationRs m1,3811,6371,631-0.3%18.1%
InterestRs m18935447734.6%152.7%
Profit before taxRs m9,0207,8669,14416.2%1.4%
TaxRs m3,0691,7542,04816.7%-33.3%
Profit after taxRs m5,9506,1127,09616.1%19.3%
Gross profit margin%23.720.220.1
Effective tax rate%34.022.322.4
Net profit margin%13.612.813.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 21.5% on a year-on-year (YoY) basis. The expenses were up by 26.4% YoY during the same period.
  • The company's operating profit increased by 3.5% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 23.7% in 3QFY18.
  • Depreciation charges increased by 18.1% and finance costs increased by 152.7% YoY, respectively.
  • Other income increased by 93.2% YoY during the quarter.
  • Net profit for the quarter increased by 19.3% YoY. Net profit margins during the quarter declined from 13.6% in 3QFY18 to 13.3% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 10.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 11.1% QoQ during the same period.
  • The company's operating profit declined by 10.6% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 20.2% in 2QFY18.
  • Net profit for the quarter increased by 16.1% QoQ, while net profit margins increased from 12.8% in 2QFY18 to 13.3% in 3QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 607.9 to Rs 766.0, registering a Gain of Rs 158.2 or around 26.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,712.7 (down 0.1%). Over the last one year it has moved down from 14,517.2 to 13,712.7, a gain of 805 points (down 5.5%).

Overall, the S&P BSE SENSEX is up 6.1% over the year.

Current Valuations

At the current price of Rs 766.0, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 19.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.8 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 11, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS